Trial Profile

A Phase 1, Open-label Study in Healthy Adult Subjects to Evaluate Effects of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-99677 and the Effects of CC-99677 on the Pharmacokinetics of Digoxin, Metformin, Methotrexate, Midazolam, Rosuvastatin, and Sulfasalazine

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gamcemetinib (Primary) ; Digoxin; Itraconazole; Metformin; Methotrexate; Midazolam; Rifampicin; Rosuvastatin; Sulfasalazine
Indications Inflammation
Focus Pharmacokinetics
Sponsors Celgene Corporation

26 Aug 2020 Planned End Date changed from 30 Apr 2021 to 2 Jun 2021.
26 Aug 2020 Planned primary completion date changed from 30 Apr 2021 to 2 Jun 2021.
09 Aug 2020 Planned End Date changed from 15 Oct 2020 to 30 Apr 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com